Gasparri Maria Luisa, Attar Rukset, Palaia Innocenza, Perniola Giorgia, Marchetti Claudia, Di Donato Violante, Farooqi Ammad Ahmad, Papadia Andrea, Panici Pierluigi Benedetti
Department of Gynecologic-Obstetrical and Urologic Sciences, "Sapienza" University of Rome, Italy E-mail :
Asian Pac J Cancer Prev. 2015;16(9):3635-8. doi: 10.7314/apjcp.2015.16.9.3635.
Several improvements in ovarian cancer treatment have been achieved in recent years, both in surgery and in combination chemotherapy with targeting. However, ovarian tumors remain the women's cancers with highest mortality rates. In this scenario, a pivotal role has been endorsed to the immunological environment and to the immunological mechanisms involved in ovarian cancer behavior. Recent evidence suggests a loss of the critical balance between immune-activating and immune-suppressing mechanisms when oncogenesis and cancer progression occur. Ovarian cancer generates a mechanism to escape the immune system by producing a highly suppressive environment. Immune-activated tumor infiltrating lymphocytes (TILs) in ovarian tumor tissue testify that the immune system is the trigger in this neoplasm. The TIL mileau has been demonstrated to be associated with better prognosis, more chemosensitivity, and more cases of optimal residual tumor achieved during primary cytoreduction. Nowadays, scientists are focusing attention on new immunologically effective tumor biomarkers in order to optimize selection of patients for recruitment in clinical trials and to identify relationships of these biomarkers with responses to immunotherapeutics. Assessing this point of view, TILs might be considered as a potent predictive immunotherapy biomarker.
近年来，卵巢癌治疗在手术以及靶向联合化疗方面均取得了多项进展。然而，卵巢肿瘤仍是死亡率最高的女性癌症。在这种情况下，免疫环境以及参与卵巢癌发生发展的免疫机制被认为起着关键作用。最近的证据表明，在肿瘤发生和癌症进展过程中，免疫激活和免疫抑制机制之间的关键平衡遭到破坏。卵巢癌通过产生高度抑制性的环境来形成一种逃避免疫系统的机制。卵巢肿瘤组织中免疫激活的肿瘤浸润淋巴细胞（TILs）证明免疫系统是这种肿瘤的触发因素。TILs环境已被证明与更好的预后、更高的化疗敏感性以及在初次肿瘤细胞减灭术中更多达到最佳残留肿瘤的病例相关。如今，科学家们正将注意力集中在新的具有免疫效应的肿瘤生物标志物上，以便优化临床试验入组患者的选择，并确定这些生物标志物与免疫治疗反应之间的关系。从这一角度评估，TILs可被视为一种有效的预测性免疫治疗生物标志物。
